https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:106 Wed 11 Apr 2018 12:13:04 AEST ]]> Short-term predictive ability of selected cardiovascular risk prediction models in a rural Bangladeshi population: a case-cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25057 Wed 09 Mar 2022 15:59:38 AEDT ]]> Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41899 PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. Methods: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration. Results: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer’s disease – outcomes for which large-scale trial data were unavailable. Conclusions: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.]]> Tue 16 Aug 2022 08:27:58 AEST ]]> Thrombolysis implementation intervention and clinical outcome: a secondary analysis of a cluster randomized trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42696 Tue 14 Nov 2023 14:44:08 AEDT ]]> Natural history and prognostic implications of left ventricular end-diastolic pressure in reperfused ST-segment elevation myocardial infarction: an analysis of the thrombolysis in myocardial infarction (TIMI) II randomized controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45386 Thu 27 Oct 2022 16:43:59 AEDT ]]> Concordance of recommendations across clinical practice guidelines for the management of hypertension in Southeast Asia with internationally reputable sources https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43237 Thu 15 Sep 2022 11:13:29 AEST ]]> Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28247 Mon 23 Sep 2019 14:19:51 AEST ]]> Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37549 Mon 15 Feb 2021 09:16:20 AEDT ]]> Patient, clinician and logistic barriers to blood pressure control among adult hypertensives in rural district hospitals in Rwanda: a cross-sectional study. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45882 6 out of 8 examined medications available in all pharmacies, cost Mon 07 Nov 2022 16:23:16 AEDT ]]>